Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial


Matasar M. J. , Capra M., ÖZCAN M., Lv F., Li W., Yanez E., ...More

LANCET ONCOLOGY, vol.22, no.5, pp.678-689, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 5
  • Publication Date: 2021
  • Doi Number: 10.1016/s1470-2045(21)00145-5
  • Title of Journal : LANCET ONCOLOGY
  • Page Numbers: pp.678-689

Abstract

Background Copanlisib, an intravenous pan-class I PI3K inhibitor, showed efficacy and safety as monotherapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma who had received at least two therapies. The CHRONOS-3 study aimed to assess the efficacy and safety of copanlisib plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma.